Facebook
Twitter
LinkedIn
Forward37th Annual Pittsburgh Schizophrenia Conference
Our featured speaker is Sir Robin Murray, FRS who is this year’s Hogarty awardee and lecturer. Sir Robin’s presentation will address cannabis use and its impact on the incidence and presentation of schizophrenia and related disorders. The evidence for Music Therapy and Cognitive Behavior Therapy in the treatment of persons with schizophrenia will be explicated by two well-known scholars in their respective fields, Drs. Silverman and Lecomte. Internal faculty and staff will describe their valiant and successful efforts in keeping two specialty medication clinics (i.e. clozapine and long acting anti-psychotic injections) open in the midst of the COVID-19 pandemic. A quality improvement project to assist long term residential patients overcome severe constipation associated with clozapine use will be described. The use of clozapine over a longer time period in Allegheny County and the clinical outcomes that have emerged will be described by our internal faculty working collaboratively with a team from the University of Pittsburgh’s School of Pharmacy and Allegheny County’s Behavioral Health Data Analytics and Outcomes group.
Attendees will hear from people with serious mental illness who will share their experiences with music to help support their recovery and this will be moderated by a professional music conductor and composer. Breakout rooms during the online conference will feature ongoing research studies, art exhibits by patients, musical performances by patients, and musical performances by physicians.
Target Audience
The conference is designed to disseminate the latest clinical and research findings to a wide audience: psychiatrists and other mental health clinicians, including nurses, social workers, psychologists, service coordinators, researchers, patients and their relatives, mental health policy administrators and others who intend to keep current regarding treatment and research in schizophrenia.
Learning Objectives
At the completion of this program, participants should be able to:
1. Assess and recognize the efforts of specialty medication clinics in providing clozapine and long acting antipsychotic injection services during the COVID-19 pandemic restrictions.
2. Recognize the importance of severe constipation and its complications associated with clozapine use and ways to mitigate this risk while continuing clozapine treatment.
3. Discuss the impact of cannabis on the incidence and presentation of psychoses.
4. Review and assess the evidence for Music Therapy in the treatment of adults with schizophrenia.
5. Review and assess the evidence for Cognitive Behavior Therapy for the treatment of persons with schizophrenia.
6. Review clinical outcomes associated with the use of clozapine in Allegheny County over a several year period.
Additional Information
| Attachment | Size |
|---|---|
 CME 37th Annual Pittsburgh Schizophrenia Conference Handout (003) approved.pdf | 432.17 KB |
Course Director
K.N. Roy Chengappa, MD
Professor of Psychiatry
University of Pittsburgh School of Medicine
Chief, Comprehensive Recovery Services
UPMC Western Psychiatric Hospital
Pittsburgh, PA
2020 Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Award Winner
Sir Robin MacGregor Murray, FRS
Professor of Psychiatric Research at the Institute of Psychiatry
King’s College London
Fellow of Royal Society
London, UK
Faculty
Michael J. Silverman, PhD, MT-BC
Professor of Music Therapy
Director of the Music Therapy Program
University of Minnesota
Minneapolis, MN
Tania Lecomte, PhD
Professor, Department of Psychology
Montreal University
Senior Researcher, FQR-S, CRIUSMM, CRIPCAS
Senior Editor RCSMC
Coordinator of the Canadian Network for Research in Schizophrenia and Psychoses
Montreal, Quebec
Shaun M. Eack, PhD
James and Noel Browne Endowed Chair
Associate Dean for Research
Professor, School of Social Work
Professor, Department of Psychiatry
University of Pittsburgh
Pittsburgh, PA
Jessica M. Gannon, MD
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Outpatient Medical Director
Comprehensive Recovery Services
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Deepak Sarpal, MD
Assistant Professor, Department of Psychiatry
University of Pittsburgh
Medical Director, STEP Clinic
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Ana M. Lupu, Pharm D
Adjunct Instructor of Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Forbes Pharmacy
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Susan Hogarty, RN, MSN
Psychiatric Clinical Nurse Specialist
Research Program Administrator
ASCEND Program
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Lori Arbutiski, RN, MSN
Nurse Manager, Outpatient
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Jessica Nichols, PharmD
Lead Pharmacist, Forbes Pharmacy
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Flavio Chamis
Composer, Conductor, Educator, Music Consultant and Producer
Pittsburgh, PA
Judith Conlogue, RN
Professional Staff Nurse
CRS Outpatient Medication Clinic
Comprehensive Recovery Services
UPMC Western Psychiatric Hospital
Pittsburgh, PA
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
The following relevant financial relationships were disclosed:
Steven D. Forman, MD, PhD Stockholder: Neurocrine
John M. Kane, MD Grant/Research Support:
Otsuka, Lundbeck, Janssen
Consultant:
Forum, Allergan, Alkermes, Eli Lilly, Genentech, Lundbeck, Intracellular Therapies, Janssen, Johnson & Johnson, Neurocrine, Otsuka, Pierre Fabre, Merck, Reviva, Roche, Sunovion, Takeda, Teva
Stockholder: Vanguard Research Group, LB Pharmaceuticals
Other: Advisory Board: Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Takeda, Teva, Pierre Fabre
Deanna L. Kelly, PharmD, BCPP Consultant: Alkermes, HLS Therapeutics
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 6.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 6.00 Attendance